Grant Details
Grant Number: |
7R01CA276594-02 Interpret this number |
Primary Investigator: |
Vandellen, Michelle |
Organization: |
University Of Oklahoma Hlth Sciences Ctr |
Project Title: |
Randomized Controlled Trial of Dyadic Financial Incentive Treatment for Dual Smoker Couples: Evaluation of Efficacy, Mechanisms, and Cost Effectiveness |
Fiscal Year: |
2024 |
Abstract
Project Summary/Abstract
Smokers partnered with other smokers (i.e., dual-smoker couples) represent ~2/3 of all smokers. Dual-
smoker couples (DSCs) are less likely to try to quit smoking and more likely to relapse during a quit attempt,
reducing overall smoking cessation rates and representing a high-risk clinical population. Despite their high
prevalence and risk for persistent smoking, however, there are limited data on smoking cessation interventions
among DSCs. Building on previous research that suggests a) financial incentive treatments (FITs) are effective
at increasing quit rates; and b) dyadic adaptations of FITs are feasible for implementation in DSCs, the proposed
randomized controlled trial (RCT) will systematically examine two adaptations of FITs to enhance smoking
cessation among DSCs. In addition to determining the efficacy of these FITs for smoking abstinence in DSCs,
we will examine mechanisms of change, secondary endpoints and outcomes, and the cost effectiveness of each
adaptation. We will address these questions in a three-group RCT that is informed by a highly supportive pilot
trial we have completed on FITs for DSCs (R21CA241570). In all conditions, treatment-seeking smokers who
are part of a DSC (i.e., targets) will receive usual care (combination fast and slow acting Nicotine Replacement
Therapy + quitting resources). In two experimental conditions (single FIT and dyadic FIT, SFT and DFIT),
participants will receive incentives for abstinence at three time points (1-, 3-, and 6-months post-baseline). In the
SFIT condition, only the target in a couple will be offered incentives; in the DFIT condition, both target and partner
in a couple will be offered incentives. Primary efficacy outcome is biochemically-verified abstinence at 6-months
post-baseline among targets. We will concurrently evaluate candidate mechanisms of change (e.g., partner
support, individual and partner motivation) to understand how FITs confer benefits and inform optimization.
Secondary outcomes are point-prevalence abstinence at 1- and 3-months during the treatment and 6-months
post-treatment (12-months post-baseline), as well as partner smoking outcomes. As FITs inherently rely on
financial resources, cost-effectiveness analysis will quantify the cost and relative cost of positive outcomes within
and across conditions. These data on the efficacy, mechanisms, and costs of FITs for DSCs will inform
population level implementation and promote successful quitting in this treatment refractory population.
Publications
None